This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunn, S. E. Articles by Barrett, J. C. Search for Related Content PubMed PubMed Citation Articles by Dunn, S. E. Articles by Barrett, J. C.

Up-Regulation of Urokinase-Type Plasminogen Activator by Insulin-like Growth Factor-I Depends upon Phosphatidylinositol-3 Kinase and Mitogen-activated Protein Kinase Kinase

National Cancer Institute, NIH, Research Triangle Park, North Carolina 27709 [S. E. D., J. S. O., D. M. C., J. C. B.], and School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 [J. V. T.]

Elevated levels of urokinase plasminogen activator-1 (uPA) and the insulin-like growth factor-I receptor (IGF-IR) are associated with breast cancer recurrence and decreased survival. It is possible that activation of IGF-IR and elevations in uPA are mechanistically linked. Our laboratory recently showed that insulin-like growth factor-I (IGF-I) induces uPA protein and mRNA in the breast cancer cell line MDA-MB-231. We also found that IGF-IR and uPA were commonly overexpressed in primary breast cancers. In this study, we investigated the signal transduction pathway through which IGF-I regulates uPA. Phosphatidylinositol 3kinase, mitogen-activated protein kinase kinase, and p70 kinase were inhibited with LY294002, PD98059, and rapamycin, respectively. Induction of uPA protein by IGF-I was partially inhibited by LY294002 (60% inhibition) or PD98059 (30% inhibition) but not by rapamycin. The production of uPA protein induced by IGF-I was blocked up to 90% by the tyrosine kinase inhibitor herbimycin A. Furthermore, herbimycin A suppressed the phosphorylation of AKT and Erk1/2. Next, we tested the impact of the signal transduction inhibitors on uPA gene expression. Both LY294002 and PD98059 were required to completely inhibit uPA mRNA expression, whereas each drug alone resulted in approximately 50% reduction in uPA expression. Next, using a minimal uPA-luciferase promoter construct containing the binding sites for the AP-1 and Ets transcription factors, we observed that IGF-I stimulated the uPA promoter via these sites. Furthermore, both Ly294002 and PD98059 were necessary to block IGF-I-stimulated uPA-Luc activity. In summary, we conclude that IGF-I requires both phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase-dependent pathways to optimally induce uPA expression. These findings suggest that the development of drugs targeting these pathways may benefit breast cancer patients at a high risk of recurrence, such as those who have primary tumors overexpressing IGF-IR and uPA.

This article has been cited by other articles:

				Y. Adachi, R. Li, H. Yamamoto, Y. Min, W. Piao, Y. Wang, A. Imsumran, H. Li, Y. Arimura, C.-T. Lee, et al. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin Carcinogenesis, August 1, 2009; 30(8): 1305 - 1313. [Abstract] [Full Text] [PDF]

				T. Fujii, A. Kawahara, Y. Basaki, S. Hattori, K. Nakashima, K. Nakano, K. Shirouzu, K. Kohno, T. Yanagawa, H. Yamana, et al. Expression of HER2 and Estrogen Receptor {alpha} Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers Cancer Res., March 1, 2008; 68(5): 1504 - 1512. [Abstract] [Full Text] [PDF]

				V. Dolgachev, M. Thomas, A. Berlin, and N. W. Lukacs Stem cell factor-mediated activation pathways promote murine eosinophil CCL6 production and survival J. Leukoc. Biol., April 1, 2007; 81(4): 1111 - 1119. [Abstract] [Full Text] [PDF]

				A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]

				S.-H. Oh, O.-H. Lee, C. P. Schroeder, Y. W. Oh, S. Ke, H.-J. Cha, R.-W. Park, A. Onn, R. S. Herbst, C. Li, et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol. Cancer Ther., November 1, 2006; 5(11): 2685 - 2695. [Abstract] [Full Text] [PDF]

				B. N. Duong, S. Elliott, D. E. Frigo, L. I. Melnik, L. Vanhoy, S. Tomchuck, H. P. Lebeau, O. David, B. S. Beckman, J. Alam, et al. AKT Regulation of Estrogen Receptor {beta} Transcriptional Activity in Breast Cancer. Cancer Res., September 1, 2006; 66(17): 8373 - 8381. [Abstract] [Full Text] [PDF]

				T. W. Bauer, R. J. Somcio, F. Fan, W. Liu, M. Johnson, D. P. Lesslie, D. B. Evans, G. E. Gallick, and L. M. Ellis Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1676 - 1682. [Abstract] [Full Text] [PDF]

				A. Srirangam, R. Mitra, M. Wang, J. C. Gorski, S. Badve, L. Baldridge, J. Hamilton, H. Kishimoto, J. Hawes, L. Li, et al. Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1883 - 1896. [Abstract] [Full Text] [PDF]

				M. Cicek, R. Fukuyama, D. R. Welch, N. Sizemore, and G. Casey Breast Cancer Metastasis Suppressor 1 Inhibits Gene Expression by Targeting Nuclear Factor-{kappa}B Activity Cancer Res., May 1, 2005; 65(9): 3586 - 3595. [Abstract] [Full Text] [PDF]

				H. Li, X. Ye, C. Mahanivong, D. Bian, J. Chun, and S. Huang Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells J. Biol. Chem., March 18, 2005; 280(11): 10564 - 10571. [Abstract] [Full Text] [PDF]

				Y. Tanaka, H. Kobayashi, M. Suzuki, N. Kanayama, and T. Terao Transforming Growth Factor-{beta}1-dependent Urokinase Up-regulation and Promotion of Invasion Are Involved in Src-MAPK-dependent Signaling in Human Ovarian Cancer Cells J. Biol. Chem., March 5, 2004; 279(10): 8567 - 8576. [Abstract] [Full Text] [PDF]

				H. Kobayashi, M. Suzuki, N. Kanayama, and T. Terao Genetic Down-regulation of Phosphoinositide 3-Kinase by Bikunin Correlates with Suppression of Invasion and Metastasis in Human Ovarian Cancer HRA Cells J. Biol. Chem., February 20, 2004; 279(8): 6371 - 6379. [Abstract] [Full Text] [PDF]

				T. O. Nielsen, H. N. Andrews, M. Cheang, J. E. Kucab, F. D. Hsu, J. Ragaz, C. B. Gilks, N. Makretsov, C. D. Bajdik, C. Brookes, et al. Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival: Potential for Intervention with 17-Allylamino Geldanamycin Cancer Res., January 1, 2004; 64(1): 286 - 291. [Abstract] [Full Text] [PDF]

				G. Zhang, B. He, and G. F. Weber Growth Factor Signaling Induces Metastasis Genes in Transformed Cells: Molecular Connection between Akt Kinase and Osteopontin in Breast Cancer Mol. Cell. Biol., September 15, 2003; 23(18): 6507 - 6519. [Abstract] [Full Text] [PDF]

				Y.-T. Tai, K. Podar, N. Mitsiades, B. Lin, C. Mitsiades, D. Gupta, M. Akiyama, L. Catley, T. Hideshima, N. C. Munshi, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling Blood, April 1, 2003; 101(7): 2762 - 2769. [Abstract] [Full Text] [PDF]

				R. Castello, A. Estelles, C. Vazquez, C. Falco, F. Espana, S. M. Almenar, C. Fuster, and J. Aznar Quantitative Real-Time Reverse Transcription-PCR Assay for Urokinase Plasminogen Activator, Plasminogen Activator Inhibitor Type 1, and Tissue Metalloproteinase Inhibitor Type 1 Gene Expressions in Primary Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1288 - 1295. [Abstract] [Full Text] [PDF]

				N. Sauvonnet, B. Pradet-Balade, J. A. Garcia-Sanz, and G. R. Cornelis Regulation of mRNA Expression in Macrophages after Yersinia enterocolitica Infection. ROLE OF DIFFERENT Yop EFFECTORS J. Biol. Chem., July 5, 2002; 277(28): 25133 - 25142. [Abstract] [Full Text] [PDF]